

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

## Nurtec ODT (rimegepant)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Nurtec ODT (rimegepant) 75 mg tablets	15 tablets per 30 days*

\*For approval of greater than 15 tablets per 30 days, the individual must meet the following criteria:

- I. Individual has a diagnosis of migraine headaches; **AND**
- II. Individual has had a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and an inadequate response to **one** of the following daily preventive therapies (AAN/AHA 2012/2015, ICSI 2013):
  - A. A tricyclic antidepressant [such as but not limited to amitriptyline, doxepin]; **OR**
  - B. A beta blocker [such as but not limited to metoprolol tartrate, propranolol, timolol, atenolol, nadolol, nebivolol]; **OR**
  - C. A calcium channel blocker [such as but not limited to nifedipine, verapamil]; **OR**
  - D. An ACE inhibitor [such as but not limited to lisinopril]; **OR**
  - E. An angiotensin receptor blocker (ARBs) [such as but not limited to candesartan]; **OR**
  - F. An alpha-2 agonist [such as but not limited to guanfacine]; **OR**
  - G. An antiepileptic [such as but not limited to divalproex sodium, sodium valproate, topiramate, carbamazepine, gabapentin]; **OR**
  - H. Other select antidepressants [such as but not limited to venlafaxine]; **OR**
  - I. Cyproheptadine (Periactin).

### APPROVAL CRITERIA

Requests for oral CGRP agents for acute migraine treatment (Nurtec ODT [rimegepant]) may be approved if the following criteria is met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to **two** oral triptans (AHS 2019); **OR**
- II. Individual has one of the following cardiovascular or non-coronary vascular contraindications to use of triptans:
  - A. Ischemic coronary artery disease (CAD) including angina pectoris, history of myocardial infarction, documented silent ischemia, coronary artery vasospasm (including Prinzmetal's angina); **OR**

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

- B. History of stroke or transient ischemic attack (TIA); **OR**
- C. Peripheral vascular disease; **OR**
- D. Ischemic bowel disease; **OR**
- E. Uncontrolled hypertension.

Nurtec ODT (rimegepant) may not be approved for the following:

- I. Individual is currently using one of the following:
  - A. A strong CYP3A4 inhibitor (such as ketoconazole, itraconazole, clarithromycin); **OR**
  - B. A strong or moderate CYP3A4 inducer (such as carbamazepine, phenytoin, St. John's wort, modafinil, rifampin); **OR**
  - C. A P-glycoprotein (P-gp) or BCRP inhibitor (such as ketoconazole, quinidine, tacrolimus, verapamil, sulfasalazine);
- OR**
- II. Individual has severe hepatic impairment (Child-Pugh C); **OR**
- III. Individual has end-stage renal disease (CRCL < 15 mL/min).

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Beithon J, Gallenberg M, Johnson K, et al. Diagnosis and Treatment of Headache. Institute for Clinical Systems Improvement. Available from: [https://www.icsi.org/guidelines\\_more/catalog\\_guidelines\\_and\\_more/catalog\\_guidelines/catalog\\_neurological\\_guidelines/headache/](https://www.icsi.org/guidelines_more/catalog_guidelines_and_more/catalog_guidelines/catalog_neurological_guidelines/headache/). Updated January 2013.
6. [The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019; 59:1-18. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/head.13456. Accessed November 26, 2019.](https://onlinelibrary.wiley.com/doi/epdf/10.1111/head.13456)
7. [Tfelt-Hansen PC. Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences. Expert Rev Neurother. 2013; 13\(9\): 961-963. Available from https://www.tandfonline.com/doi/pdf/10.1586/14737175.2013.832851. Accessed April 5, 2019.](https://www.tandfonline.com/doi/pdf/10.1586/14737175.2013.832851)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.